Login / Signup

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events.

Daniel Vilarim AraújoThiago Pimentel MunizAnjie YangSareh KeshavarziHadas SorotskyMarcus O ButlerSamuel SaibilAnna SpreaficoDavid Hogg
Published in: Current oncology (Toronto, Ont.) (2021)
In this dose-limited setting, infliximab was effective in resolving irAEs and did not induce hepatotoxicity.
Keyphrases
  • drug induced
  • ulcerative colitis
  • metabolic syndrome
  • skeletal muscle
  • replacement therapy
  • weight loss
  • glycemic control
  • patients with inflammatory bowel disease